202 related articles for article (PubMed ID: 20961309)
61. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.
Rinderknecht M; Villa A; Ballmer-Hofer K; Neri D; Detmar M
PLoS One; 2010 Aug; 5(8):e11941. PubMed ID: 20689828
[TBL] [Abstract][Full Text] [Related]
62. Pathways targeting tumor lymphangiogenesis.
Wissmann C; Detmar M
Clin Cancer Res; 2006 Dec; 12(23):6865-8. PubMed ID: 17145802
[TBL] [Abstract][Full Text] [Related]
63. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
64. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Lohela M; Bry M; Tammela T; Alitalo K
Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
[TBL] [Abstract][Full Text] [Related]
65. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF.
Endo A; Fukuhara S; Masuda M; Ohmori T; Mochizuki N
J Recept Signal Transduct Res; 2003; 23(2-3):239-54. PubMed ID: 14626450
[TBL] [Abstract][Full Text] [Related]
66. [Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer].
Chen YN; Gu Y
Ai Zheng; 2009 Dec; 28(12):1337-43. PubMed ID: 19958632
[TBL] [Abstract][Full Text] [Related]
67. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.
Wuest TR; Carr DJ
J Exp Med; 2010 Jan; 207(1):101-15. PubMed ID: 20026662
[TBL] [Abstract][Full Text] [Related]
68. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
[TBL] [Abstract][Full Text] [Related]
69. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.
Bando H; Weich HA; Brokelmann M; Horiguchi S; Funata N; Ogawa T; Toi M
Br J Cancer; 2005 Feb; 92(3):553-61. PubMed ID: 15668703
[TBL] [Abstract][Full Text] [Related]
70. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis.
Mimura T; Amano S; Usui T; Kaji Y; Oshika T; Ishii Y
Exp Eye Res; 2001 Jan; 72(1):71-8. PubMed ID: 11133184
[TBL] [Abstract][Full Text] [Related]
71. Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis.
Nakao S; Zandi S; Hata Y; Kawahara S; Arita R; Schering A; Sun D; Melhorn MI; Ito Y; Lara-Castillo N; Ishibashi T; Hafezi-Moghadam A
Blood; 2011 Jan; 117(3):1081-90. PubMed ID: 20705758
[TBL] [Abstract][Full Text] [Related]
72. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis.
Durré T; Morfoisse F; Erpicum C; Ebroin M; Blacher S; García-Caballero M; Deroanne C; Louis T; Balsat C; Van de Velde M; Kaijalainen S; Kridelka F; Engelholm L; Struman I; Alitalo K; Behrendt N; Paupert J; Noel A
Nat Commun; 2018 Dec; 9(1):5178. PubMed ID: 30518756
[TBL] [Abstract][Full Text] [Related]
73. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis.
Lahdenranta J; Hagendoorn J; Padera TP; Hoshida T; Nelson G; Kashiwagi S; Jain RK; Fukumura D
Cancer Res; 2009 Apr; 69(7):2801-8. PubMed ID: 19318557
[TBL] [Abstract][Full Text] [Related]
74. Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.
Garrafa E; Caprara V; Di Castro V; Rosanò L; Bagnato A; Spinella F
Life Sci; 2012 Oct; 91(13-14):638-43. PubMed ID: 22552325
[TBL] [Abstract][Full Text] [Related]
75. Evolutionary Differences in the Vegf/Vegfr Code Reveal Organotypic Roles for the Endothelial Cell Receptor Kdr in Developmental Lymphangiogenesis.
Vogrin AJ; Bower NI; Gunzburg MJ; Roufail S; Okuda KS; Paterson S; Headey SJ; Stacker SA; Hogan BM; Achen MG
Cell Rep; 2019 Aug; 28(8):2023-2036.e4. PubMed ID: 31433980
[TBL] [Abstract][Full Text] [Related]
76. VEGFR signaling during lymphatic vascular development: From progenitor cells to functional vessels.
Secker GA; Harvey NL
Dev Dyn; 2015 Mar; 244(3):323-31. PubMed ID: 25399804
[TBL] [Abstract][Full Text] [Related]
77. [Effect of recombinant VEGF-C secreted from eukaryotic cells on proliferation and chemotherapy-induced apoptosis of leukemic cells].
Ding KY; Bai X; Dai L; Dong NZ; Ruan CG
Ai Zheng; 2005 Sep; 24(9):1037-42. PubMed ID: 16159421
[TBL] [Abstract][Full Text] [Related]
78. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance.
Wada H; Satoh N; Kitaoka S; Ono K; Morimoto T; Kawamura T; Nakano T; Fujita M; Kita T; Shimatsu A; Hasegawa K
Atherosclerosis; 2010 Feb; 208(2):512-7. PubMed ID: 19695569
[TBL] [Abstract][Full Text] [Related]
79. Vascular endothelial growth factor D is dispensable for development of the lymphatic system.
Baldwin ME; Halford MM; Roufail S; Williams RA; Hibbs ML; Grail D; Kubo H; Stacker SA; Achen MG
Mol Cell Biol; 2005 Mar; 25(6):2441-9. PubMed ID: 15743836
[TBL] [Abstract][Full Text] [Related]
80. Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia.
Stachon A; Aweimer A; Stachon T; Tannapfel A; Thoms S; Ubrig B; Köller M; Krieg M; Truss MC
Growth Factors; 2009 Apr; 27(2):71-8. PubMed ID: 19199116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
